Patents by Inventor Sean Dalziel

Sean Dalziel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9949963
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: April 24, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Sean Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • Publication number: 20160287572
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Application
    Filed: February 10, 2016
    Publication date: October 6, 2016
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Sean Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • Publication number: 20150111838
    Abstract: This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin. As well as cyclodextrin complexation methods of formulating a peptide proteasome inhibitor (e.g., a compound of formula (1)-(5) or a pharmaceutically acceptable salt thereof) with one or more cyclodextrins. Such methods substantially increase the solubility and stability of these proteasome inhibitors and facilitate both their manufacture and administration. For example, homogenous solutions of a compound of formula (5) (carfilzomib) can be obtained at a pharmaceutically useful pH (e.g., about 3.5) and at higher concentrations (e.g., about 5 mg/mL) than could be obtained without one or more cyclodextrins and the processes of complexation between the compound and one or more cyclodextrins provided herein.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 23, 2015
    Inventors: Evan Lewis, Peter Schwonek, Sean Dalziel, Mouhannad Jumaa
  • Patent number: 8816091
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: August 26, 2014
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Sean Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • Publication number: 20140080856
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Application
    Filed: August 13, 2013
    Publication date: March 20, 2014
    Applicant: THERAVANCE, INC.
    Inventors: Sean Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • Publication number: 20130303482
    Abstract: This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin. Such methods substantially increase the solubility and stability of these proteasome inhibitors and facilitate both their manufacture and administration.
    Type: Application
    Filed: September 13, 2012
    Publication date: November 14, 2013
    Inventors: Evan Lewis, Peter Shwonek, Sean Dalziel, Mouhannad Jumaa
  • Publication number: 20130303465
    Abstract: This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin. Such methods substantially increase the solubility and stability of these proteasome inhibitors and facilitate both their manufacture and administration.
    Type: Application
    Filed: September 13, 2012
    Publication date: November 14, 2013
    Inventors: Evan Lewis, Peter Shwonek, Sean Dalziel, Mouhannad Jumaa
  • Patent number: 8143279
    Abstract: The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds. The invention further relates to crystalline forms of a compound of formula (I).
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: March 27, 2012
    Assignee: Theravance, Inc.
    Inventors: Robert Murray McKinnell, Daniel D. Long, Sean Dalziel, Kirsten M. Phizackerley
  • Publication number: 20110184008
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Application
    Filed: April 6, 2011
    Publication date: July 28, 2011
    Applicant: THERAVANCE, INC.
    Inventors: Sean Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • Patent number: 7943772
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamideor a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: May 17, 2011
    Assignee: Theravance, Inc.
    Inventors: Sean Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • Patent number: 7622508
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: November 24, 2009
    Assignee: Theravance, Inc.
    Inventors: Daniel D. Long, Timothy J. Church, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades, Priscilla M. Van Dyke, Sean Dalziel, Leticia Maria Preza
  • Publication number: 20090209582
    Abstract: The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds. The invention further relates to crystalline forms of a compound of formula (I).
    Type: Application
    Filed: May 24, 2006
    Publication date: August 20, 2009
    Inventors: Robert Murray McKinnell, Roland Gendron, Lan Jiang, Seok-ki Choi, Daniel D. Long, Paul R. Fatheree, Daniel Marquess, Sean Dalziel, Kirsten M. Phizackerley
  • Publication number: 20080207676
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Application
    Filed: February 27, 2008
    Publication date: August 28, 2008
    Inventors: Sean Dalziel, Leticia M. Preza, Miroslave Rapta, Pierre-Jean Colson
  • Publication number: 20070244157
    Abstract: The invention provides crystalline forms of the novel benzimidazole-carboxamide 5-HT4 receptor agonist compound, 4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester. The invention also provides pharmaceutical compositions comprising the crystalline compound, methods of using the compound to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing crystalline forms of the compound.
    Type: Application
    Filed: May 30, 2007
    Publication date: October 18, 2007
    Inventors: Sean Dalziel, Kirsten Phizackerley
  • Publication number: 20070219278
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: February 28, 2007
    Publication date: September 20, 2007
    Inventors: Daniel D. Long, Timothy J. Church, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades, Priscilla M. Van Dyke, Sean Dalziel, Leticia Maria Preza
  • Publication number: 20060270854
    Abstract: The invention provides crystalline forms of the novel benzimidazole-carboxamide 5-HT4 receptor agonist compound, 4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester. The invention also provides pharmaceutical compositions comprising the crystalline compound, methods of using the compound to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing crystalline forms of the compound.
    Type: Application
    Filed: May 24, 2006
    Publication date: November 30, 2006
    Inventors: Sean Dalziel, Kirsten Phizackerley, Robert McKinnell, Roland Gendron, Seok-ki Choi, Daniel Long
  • Publication number: 20060205949
    Abstract: The invention provides crystalline naphthalene-1,5-disulfonic acid salts of biphenyl-2-ylcarbamic acid 1-{2-[5-(4-hydroxybenzylamino)pentylcarbamoyl]ethyl}piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The invention also provides pharmaceutical compositions comprising the crystalline compounds or prepared using such compounds; processes and intermediates for preparing the crystalline compounds; and methods of using the compounds to treat pulmonary disorders.
    Type: Application
    Filed: March 9, 2006
    Publication date: September 14, 2006
    Inventors: Sean Dalziel, Cristin Hubbard, Viengkham Malathong
  • Publication number: 20060068019
    Abstract: A process for coating a polyunsaturated fatty acid (PUFA)-containing carrier particle or a PUFA matrix particle, or a liquid pharmaceutical-containing carrier particle or a liquid pharmaceutical matrix particle. Also disclosed are such particles made by the process of the invention and foods, pharmaceuticals, beverages, nutritional supplements, infant formula, pet food and animal feed with incorporate such particles.
    Type: Application
    Filed: August 14, 2003
    Publication date: March 30, 2006
    Inventors: Sean Dalziel, Thomas Friedmann, George Schurr
  • Publication number: 20050287077
    Abstract: The present invention relates to processes for preparing a stable sol of medicament and hydrofluorocarbon, and for preparing medicament delivery devices containing said sol. This invention also relates to a sol composition resulting from said process. This invention further relates to apparatuses for preparing said medicament delivery devices.
    Type: Application
    Filed: February 9, 2005
    Publication date: December 29, 2005
    Applicant: James E. Shipley
    Inventors: Joseph Creazzo, Sean Dalziel, Henricus Jacobus Gommeren, John Green
  • Publication number: 20050258288
    Abstract: The present invention relates to a media mill system and a method using the same to produce fine and ultra-fine particles useful in diagnostic agents, pharmaceuticals, agrochemicals, nutraceuticals and the like.
    Type: Application
    Filed: November 26, 2004
    Publication date: November 24, 2005
    Inventors: Sean Dalziel, Gary Foggin, William Ford, Henricus Gommeren